Novartis has announced that its Phase III INSIST study shows that its once-daily Onbrez Breezhaler indacaterol DPI produces better bronchodilation in COPD patients than does twice-daily salmeterol. Onbrez also reduced the need for rescue medication, according to the data presented. The FDA has requested additional clinical data from Novartis for consideration of US regulatory approval, and the company says that it plans to file that data in November. Read the company’s press release.
Phase III data shows Onbrez better for COPD than salmeterol
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
